Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

OncoGenex Pharmaceuticals To Webcast ASCO Reception On May 30, 2009
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company will hold a live webcast and conference call of presentations made at an OncoGenex hosted reception during the 2009 American Society of Clinical Oncology Annual Meeting (ASCO) on Saturday, May 30, 2009. The webcast will begin at 7:10 p.m. EDT.

Fate In Fly Sensory Organ Precursor Cells Could Explain Human Immune Disorder
Notch signaling helps determine the fate of a number of different cell types in a variety of organisms, including humans. In an article that appears in the current issue of Nature Cell Biology, researchers at Baylor College of Medicine report that a new finding about the Notch signaling pathway in sensory organ precursor cells in the fruit fly could explain the mystery behind an immunological disorder called Wiskott-Aldrich syndrome.
News of the day
Former Health Insurance Spokesman Criticizes Industry Practices
A former health insurance spokesman speaks out against insurance practices. The Wall Street Journal/Dow Jones reports: "Wendell Potter, former chief spokesman for health insurer Cigna Corp., describes himself in his Twitter bio as a "journalist who spent 20 years undercover as HMO PR flack, now writing all about it." While Potter chuckles about the line, he is serious about his foray into the U.S. health reform debate, where he is campaigning for a public health-plan option and, with mild delivery and tough words, targeting what he calls "deceptive and dishonest" tactics of a for-profit health insurance industry that"s fighting such a plan."
Medical Devices

Tekmira Pharmaceuticals Initiates ApoB SNALP Phase 1 Clinical Trial

Tekmira Pharmaceuticals Corporation (TSX:TKM) announced that it has initiated a Phase 1 human clinical trial for ApoB SNALP. ApoB SNALP, Tekmira"s lead RNAi therapeutic product candidate, is being developed as a treatment for patients with elevated low-density lipoprotein (LDL) cholesterol, or "bad" cholesterol, who are not well served by current therapy. ApoB SNALP is designed to reduce the production of apolipoprotein B (ApoB), a protein produced in the liver that plays a central role in cholesterol metabolism. Dr. Mark J. Murray, Tekmira"s President and CEO, said "We are very excited to initiate the ApoB SNALP Phase 1 clinical trial representing our first RNAi therapeutic clinical trial and an important milestone for Tekmira. Our preclinical data package supports ApoB as an excellent target for LDL cholesterol lowering and we believe ApoB SNALP is the most advanced RNAi therapeutic targeting a metabolic condition. We expect to complete the Phase 1 clinical trial in early 2010." The Phase 1 clinical trial will evaluate the safety, tolerability and pharmacokinetics of escalating single doses of ApoB SNALP in approximately 30 patients with elevated LDL cholesterol. Each dosing cohort will include four patients; three patients will receive ApoB SNALP and one patient will receive a placebo. The trial is also designed to provide preliminary data on the ability of ApoB SNALP to lower serum LDL cholesterol levels. Patients whose LDL cholesterol is reduced by greater than 15% from baseline will be followed until their LDL cholesterol levels return to baseline. Tekmira"s therapeutic approach is to target ApoB, a protein synthesized in the liver that is essential to the assembly and secretion of very low density lipoprotein (VLDL), a precursor to LDL, both of which are required for the transport and metabolism of cholesterol. ApoB SNALP consists of small interfering RNA (siRNA), designed to silence ApoB, encapsulated in a SNALP formulation. ApoB SNALP is delivered with high efficiency into the liver hepatocytes, the cells which produce ApoB, where the siRNA acts to silence the mRNA coding for ApoB protein resulting in a decrease in circulating VLDL and LDL. The therapeutic activity of ApoB SNALP has been demonstrated in preclinical models of high cholesterol. Rodents fed a high fat diet demonstrate a 50-100% increase in total cholesterol in the blood. A single ApoB SNALP treatment can overcome such diet-induced high cholesterol, returning blood cholesterol levels to normal. The suppressive effects of a single ApoB SNALP dose lasts for several weeks in preclinical models of high cholesterol. About RNAi and SNALP RNAi drugs have the potential to treat human diseases by "switching-off" disease causing genes. The technology, representing one of the most promising and rapidly advancing frontiers in biology and drug discovery, was awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi drugs, such as siRNA, require delivery technology to be administered systemically. In preclinical studies, Tekmira"s SNALP (stable nucleic acid-lipid particles) technology has been shown to be a safe and effective way to deliver RNAi drugs to disease sites. Tekmira believes it has a leading intellectual property position in the field of siRNA delivery. Tekmira Pharmaceuticals Corporation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009